TUCSON, Ariz., April 7, 2015 /PRNewswire/ -- Twelve abstracts and posters on the SynCardia temporary Total Artificial Heart will be part of the 35th Annual Meeting and Scientific Sessions by The International Society for Heart & Lung Transplantation (ISHLT).
The annual international gathering will be April 15-18, 2015, in Nice, France.
“With more than 1,400 SynCardia Total Artificial Heart implants worldwide, surgeons and heart failure cardiologists have researched and provided abstracts on the SynCardia Heart,” says Michael P. Garippa, CEO and President of SynCardia Systems, Inc. “These abstracts provide data documenting the value of SynCardia’s Total Artificial Heart technology.”
Key SynCardia Heart presentations at the meeting include multiple-center abstracts:
- “Results of the SynCardia temporary Total Artificial Heart (TAH-t) Postmarket Surveillance Study (PSS) vs. Pre-Market Approval (PMA),” 6:20 p.m. Friday, April 17, during Mini-Oral Session 7: “Mechanical Circulatory Support: Apocalypse Tomorrow,” 6-7 p.m., in the Athena Room.
- “The Use of a Portable Driver for the Total Artificial Heart in the United States: The Freedom Driver System Study,” 6:50 p.m. Friday, April 17, during the Mini-Oral Session 7: “Mechanical Circulatory Support: Apocalypse Tomorrow,” 6-7 p.m., in the Athena Room.
Here is the schedule of other key presentations regarding the SynCardia Total Artificial Heart:
- “Reliability of the Freedom Driver After Total Artificial Heart Implantation,” Poster Session 1, “Mechanical Circulatory Support,” 7-8 p.m. Wednesday, April 15, in Agora 2 Room.
- “Risk of Neurologic Complications in Patients With Total Artificial Heart,” Poster Session 1, “Mechanical Circulatory Support,” 7-8 p.m. Wednesday, April 15, in Agora 2 Room.
- “The Total Artificial Heart (TAH) Experience at Cedar Sinai Medical Center,” Poster Session 1, “Mechanical Circulatory Support,” 7-8 p.m. Wednesday, April 15, in Agora 2 Room.
- “Virtual Implantation of the 50cc Total Artificial Heart,” 12:15 p.m. Friday, April 17, during Concurrent Session 25: “Pump Up the Jam, Don’t Jam Up the Pump! VAD Management and Complications,” 11 a.m.-12:30 p.m., in the Erato/Uranie Room.
For additional information, please visit: http://www.syncardia.com/
Like SynCardia on Facebook
Follow SynCardia on Twitter @SynCardia
Connect with SynCardia on LinkedIn
Share and Discover on Google+
About the SynCardia temporary Total Artificial Heart
SynCardia Systems, Inc. in Tucson, Arizona is the manufacturer of the world’s first and only FDA, Health Canada and CE approved Total Artificial Heart for use as a bridge to transplant for people suffering from end-stage biventricular heart failure in which both ventricles can no longer pump enough blood for a person to survive.
More than 1,400 implants of the SynCardia Total Artificial Heart account for over 400 patient years of life on the device. Since January 2010 more than 600 SynCardia Hearts have been implanted.
The youngest patient to receive a SynCardia Heart was 9 years old; the oldest was 80 years old. The longest a patient has lived with a SynCardia Heart was nearly four years (1,374 days) before receiving a successful donor heart transplant.
SynCardia Systems also manufactures the Freedom® portable driver, which powers the SynCardia Heart while allowing clinically stable patients to be discharged from the hospital and live at home and in their communities. The Freedom driver has been used by more than 200 patients, accounting for over 130 patient years of support.
Photo - http://photos.prnewswire.com/prnh/20150406/196903
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/syncardia-total-artificial-heart-featured-in-12-ishlt-abstracts-300061826.html
SOURCE SynCardia Systems, Inc.
Help employers find you! Check out all the jobs and post your resume.
